V
Vincent Houe
Publications - 12
Citations - 797
Vincent Houe is an academic researcher. The author has contributed to research in topics: Lapatinib & Capecitabine. The author has an hindex of 6, co-authored 12 publications receiving 653 citations.
Papers
More filters
Journal ArticleDOI
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
J. Randolph Hecht,Yung-Jue Bang,Shukui K. Qin,Hyun Cheol Chung,Jianming Xu,Joon Oh Park,Krzysztof Jeziorski,Yaroslav Shparyk,Paulo M. Hoff,Alberto Sobrero,Pamela Salman,Jin Li,Svetlana A. Protsenko,Zev A. Wainberg,Marc Buyse,Karen Afenjar,Vincent Houe,Agathe Garcia,Tomomi Kaneko,Yingjie Huang,Saba Khan-Wasti,Sergio Santillana,Michael F. Press,Dennis J. Slamon +23 more
TL;DR: Addition of lapatinib to CapeOx did not increase OS in patients with HER2-amplified gastroesophageal adenocarcinoma, and no correlation was observed between HER2 immunohistochemistry status and survival.
Journal ArticleDOI
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial
John R. Mackey,Miguel Martin,Tadeusz Pienkowski,Janusz Rolski,Jean-Paul Guastalla,Amer Sami,John A. Glaspy,Eva Juhos,Andrew M Wardley,Tommy Fornander,John D. Hainsworth,Robert E. Coleman,Manuel Modiano,J. Vinholes,Tamás Pintér,Álvaro Rodríguez-Lescure,Bruce Colwell,Pierre Whitlock,Louise Provencher,Kara Laing,David Walde,Chris Price,Judith Hugh,Barrett H. Childs,Kimberly Bassi,Mary Ann Lindsay,Véronique Wilson,Matthieu Rupin,Vincent Houe,C Vogel +29 more
TL;DR: The results provide evidence that the initial therapeutic outcomes seen at the 5-year follow-up with a docetaxel-containing adjuvant regimen are maintained at 10 years, however, a substantial percentage of patients had a decrease in left ventricular ejection fraction, probably caused by anthracycline therapy, which warrants further investigation.
Journal ArticleDOI
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial
Michael P. Chu,J. Randolph Hecht,Dennis J. Slamon,Zev A. Wainberg,Yung-Jue Bang,Paulo M. Hoff,Alberto Sobrero,Shukui Qin,Karen Afenjar,Vincent Houe,Karen King,Sheryl Koski,Karen E. Mulder,Julie A. Price Hiller,Andrew Scarfe,Jennifer L. Spratlin,Yingjie J. Huang,Saba Khan-Wasti,Neil Chua,Michael B. Sawyer +19 more
TL;DR: This secondary analysis of TRIO-013 compares capecitabine and oxaliplatin (CapeOx) with or without lapatinib in 545 patients with ERBB2/HER2-positive metastatic gastroesophageal cancer to determine if gastric acid suppressants such as proton pump inhibitors (PPIs) may impair cape citabine efficacy.
Journal ArticleDOI
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial
John R. Mackey,Tadeusz Pienkowski,John Crown,Saeed Sadeghi,Miguel Martín,A. Chan,Mansoor N. Saleh,S. Sehdev,Louise Provencher,Vladimir Semiglazov,Michael F. Press,Guido Sauter,Mary-Ann Lindsay,Vincent Houe,M. Buyse,P. Drevot,S. Hitier,S. Bensfia,Wolfgang Eiermann +18 more
TL;DR: This 10-year analysis of the BCIRG-005 trial confirmed that the efficacy of TAC was not superior to AC → T in women with node-positive early breast cancer, and the TAC regimen with G-CSF support provides shorter adjuvant treatment duration with less toxicity.
Journal ArticleDOI
A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer.
Isabelle Ray-Coquard,Paul Haluska,Seamus O'Reilly,Paul Cottu,Lorraine Elit,Diane Provencher,Matthias W. Beckmann,Linda D. Bosserman,Sylvie Jacod,Vincent Houe,Robert D. Loberg,John A. Glaspy,Beth Y. Karlan,Dennis J. Slamon,Gottfried E. Konecny +14 more
TL;DR: Ganitumab (AMG 479), a fully human monoclonal antibody against IGF-1R that blocks binding of IGF1 and IGF2, were evaluated in asymptomatic patients with platinum-sensitive recurrent OC, highlighting the potential of developing predictive biomarkers for patient selection.